Medicare Enrolled
Dr. Wilfredo Blasini, M.D.
Hematology (Pathology) Physician · Fort Myers, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Blasini from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Blasini? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Blasini
Dr. Wilfredo Blasini is a hematology (pathology) physician in Fort Myers, FL, with 18 years in practice. Based on federal Medicare data, Dr. Blasini performed 828,110 Medicare services across 413,426 unique beneficiaries.
Between the years covered by Open Payments, Dr. Blasini received a total of $190 from 4 pharmaceutical and/or device companies across 5 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology (pathology) physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Blasini is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 3% volume in FL$ $190 industry payments
Medicare Practice Summary
Medicare Utilization ↗828,110
Medicare services
Top 3% in FL for hematology (pathology) physician
413,426
Unique beneficiaries
$20
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~46,006 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Comprehensive metabolic blood panel | 175,915 | $10 | $39 |
| Ferritin level test (iron stores) | 67,817 | $13 | $50 |
| Immunoglobulin level test | 63,299 | $9 | $34 |
| Iron level test | 63,237 | $6 | $24 |
| Measurement of immunoglobulin light chains | 42,112 | $17 | $50 |
| Iron binding capacity test | 41,042 | $9 | $32 |
| Vitamin B-12 level test | 36,505 | $15 | $56 |
| Lactate dehydrogenase (enzyme) level | 32,775 | $6 | $23 |
| Flow cytometry, additional marker | 26,651 | $19 | $120 |
| Protein measurement, serum | 23,468 | $11 | $51 |
| Carcinoembryonic antigen (cea) protein level | 23,163 | $19 | $70 |
| Folic acid level test | 22,590 | $14 | $54 |
| Thyroid stimulating hormone (TSH) test | 22,330 | $16 | $62 |
| Transferrin (iron binding protein) level | 21,381 | $12 | $44 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 18,750 | $20 | $75 |
| Immunologic analysis technique on serum (immunofixation) | 18,738 | $22 | $80 |
| Magnesium level test | 18,687 | $7 | $25 |
| PSA test (prostate cancer screening) | 9,210 | $18 | $68 |
| Cortisol (hormone) measurement, total | 6,665 | $16 | $46 |
| Uric acid level test | 5,289 | $4 | $17 |
| Beta-2 microglobulin (protein) level | 4,648 | $16 | $60 |
| Detection of infectious agent antibody, quantitative | 4,244 | $15 | $38 |
| Vitamin D level test | 4,205 | $29 | $105 |
| Basic metabolic blood panel | 4,176 | $8 | $31 |
| Hepatitis b core antibody measurement | 4,145 | $12 | $41 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 4,092 | $20 | $75 |
| Haptoglobin (serum protein) level | 3,773 | $12 | $46 |
| Tissue staining for diagnosis, additional | 3,717 | $59 | $164 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 3,678 | $20 | $75 |
| Phosphate level test | 3,573 | $5 | $18 |
| Erythropoietin (protein) level | 3,354 | $18 | $67 |
| Tissue culture for tumor disorders of bone marrow and blood cells | 3,207 | $141 | $430 |
| Free thyroxine (T4) test | 2,954 | $9 | $31 |
| Special stained specimen slides to examine tissue including interpretation and report | 2,938 | $56 | $160 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 2,680 | $10 | $36 |
| Microscopic genetic analysis of tissue, computer-assisted technology, initial procedure, each multiplex procedure | 2,098 | $240 | $579 |
| C-reactive protein test (inflammation marker) | 1,837 | $5 | $12 |
| Targeted genomic sequence analysis panel of dna or combine dna and rna of 51 or greater genes associated with blood and lymphatic system disorders | 1,748 | $2,853 | $7,299 |
| Lipid panel (cholesterol and triglycerides) | 1,681 | $13 | $49 |
| Bilirubin level, direct | 1,620 | $5 | $19 |
| Chromosome analysis for genetic defects, additional karyotypes, each study | 1,613 | $33 | $88 |
| Interpretation and report of genetic testing | 1,600 | $26 | $87 |
| Chromosome analysis for genetic defects, analyze 20-25 cells | 1,564 | $141 | $427 |
| Hemoglobin analysis and measurement, electrophoresis | 1,191 | $13 | $56 |
| Flow cytometry technique for dna or cell analysis, first marker | 1,171 | $59 | $201 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 1,166 | $66 | $268 |
| Thyroid hormone, t3 measurement, free | 1,112 | $17 | $54 |
| Tissue pathology examination, moderate complexity | 1,045 | $49 | $228 |
| Hemoglobin A1c test (diabetes monitoring) | 1,001 | $9 | $33 |
| Preparation of specimen, manual | 995 | $141 | $417 |
| Alpha-fetoprotein (afp) level, serum | 985 | $16 | $60 |
| Tissue staining for diagnosis, initial | 873 | $68 | $237 |
| Blood creatinine level | 752 | $5 | $19 |
| Hepatitis c antibody measurement | 705 | $14 | $50 |
| Rheumatoid factor level | 628 | $6 | $20 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 622 | $18 | $56 |
| Preparation of tissue for examination by removing any calcium present | 543 | $14 | $48 |
| Lipase (fat enzyme) level | 542 | $7 | $24 |
| Creatine kinase (cardiac enzyme) level, total | 500 | $6 | $24 |
| Amylase (enzyme) level | 498 | $6 | $24 |
| Chemical receptor analysis | 475 | $36 | $125 |
| Bone marrow, smear interpretation | 468 | $55 | $252 |
| Hepatitis b core antibody (igm) measurement | 422 | $12 | $40 |
| Liver function blood test panel | 380 | $8 | $30 |
| Homocysteine (amino acid) level | 350 | $18 | $60 |
| Screening examination of specimen cells, screening and interpretation | 339 | $53 | $134 |
| Chromosome analysis for genetic defects, additional cells counted, each study | 292 | $26 | $65 |
| Parathyroid hormone level test | 231 | $40 | $146 |
| Thyroxine (thyroid chemical), total | 222 | $7 | $26 |
| Blood potassium level | 151 | $5 | $17 |
| Triglycerides level | 134 | $6 | $22 |
| Gonadotropin, chorionic (reproductive hormone) level | 118 | $15 | $55 |
| Cell examination of specimen, selective cellular enhancement technique | 109 | $53 | $164 |
| Genetic sequencing localization, initial procedure | 102 | $140 | $438 |
| Genetic sequencing localization, each additional procedure | 97 | $105 | $274 |
| Kidney function blood test panel | 95 | $8 | $32 |
| Gene analysis (janus kinase 2) targeted sequence analysis | 89 | $179 | $498 |
| Gene analysis (calreticulin), common variants | 87 | $118 | $327 |
| Cholesterol level | 73 | $4 | $16 |
| Gene analysis (mpl proto-oncogene, thrombopoietin receptor) sequence analysis of exon 10 | 72 | $175 | $482 |
| Glutamyltransferase (liver enzyme) level | 67 | $7 | $27 |
| Molecular pathology procedure; physician interpretation and report | 55 | $37 | $138 |
| Translocation analysis (bcr/abl1) other breakpoint | 49 | $210 | $644 |
| Chromosome analysis for genetic defects, count 5 cells | 49 | $259 | $700 |
| Translocation analysis (bcr/abl1) major breakpoint | 48 | $160 | $410 |
| Translocation analysis (bcr/abl1) minor breakpoint | 48 | $142 | $410 |
| Prostate cancer screening; prostate specific antigen test (psa) | 47 | $19 | $51 |
| Urea nitrogen level to assess kidney function, quantitative | 45 | $4 | $15 |
| Gonadotropin, follicle stimulating (reproductive hormone) level | 44 | $18 | $64 |
| Complete blood count (CBC) with differential | 44 | $8 | $29 |
| Calcium level, total | 42 | $5 | $19 |
| Gonadotropin, luteinizing (reproductive hormone) level | 40 | $18 | $64 |
| Measurement of total estradiol (hormone) | 39 | $27 | $189 |
| Gonadotropin, chorionic (reproductive hormone) measurement | 27 | $15 | $42 |
| Flow cytometry technique for dna or cell analysis, 2 to 8 markers | 25 | $28 | $152 |
| Gene analysis (mpl proto-oncogene, thrombopoietin receptor) for detection of common variants | 19 | $147 | $451 |
| Gene analysis (janus kinase 2) variant | 18 | $90 | $275 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$190
Total received (2019-2024)
Avg $63/year across 3 years
Top 48% in FL for hematology (pathology) physician
4
Companies
5
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$190 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$17
2023$48
2019$125
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Genentech USA, Inc.
$125
Adaptive Biotechnologies Corporation
$30
Janssen Biotech, Inc.
$19
AstraZeneca Pharmaceuticals LP
$17
Top 3 companies account for 90.9% of total payments
Associated products mentioned in payments ›
RYBREVANT · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $0 per 100 Medicare services performed
Geographic Context
Hematology (Pathology) Physicians within 10 mi
3
Per 100K population
0.4
County median income
$73,099
Nearest hospital
LEE MEMORIAL HOSPITAL
2.8 mi
2.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Blasini is a mixed practice specialist, with above-average Medicare volume (top 3% in FL), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Blasini experienced with comprehensive metabolic blood panel?
Based on Medicare claims data, Dr. Blasini performed 175,915 comprehensive metabolic blood panel services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Blasini receive payments from pharmaceutical companies?
Yes. Dr. Blasini received a total of $190 from 4 companies across 5 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Blasini's costs compare to other hematology (pathology) physicians in Fort Myers?
Dr. Blasini's average Medicare payment per service is $20. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Blasini) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology (Pathology) Physicians in Fort Myers
Browse hematology (pathology) physicians in Fort Myers ranked by procedure volume and transparency data.
Highest volume
Top Hematology (Pathology) Physicians in FL
Hematology (Pathology) Physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology (Pathology) Physicians in FL
Which FL hematology (pathology) physicians receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc..
By company
Adaptive Biotechnologies Corporation Payments to Doctors
See all physicians who received payments from Adaptive Biotechnologies Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology